Senolytics: A Novel Strategy for Neuroprotection in ALS?

Area of Science:

• Neuroscience
• Cellular Biology
• Drug Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal motor neurodegenerative disease with limited treatment options.
• Cellular dysfunction in astrocytes, microglia, and motor neurons contributes to neuroinflammation and neurodegeneration in ALS.
• Damage to motor neurons leads to progressive muscle weakness and respiratory failure.

Purpose of the Study:

• To review the role of cellular senescence in ALS pathogenesis.
• To explore senolytic agents and their mechanisms of action for potential ALS therapies.
• To inform future drug discovery efforts for ALS.

Main Methods:

• Literature review of cellular senescence pathways in ALS.
• Analysis of senolytic agents and their mechanisms.
• Discussion of therapeutic strategies targeting senescent glial cells.

Main Results:

• Cellular senescence in glial cells is implicated in motor neuron degeneration in ALS.
• Senolytic agents show potential for clearing senescent cells.
• Targeting senescent glial cells represents a promising, yet unproven, therapeutic avenue for ALS.

Conclusions:

• Cellular senescence is a key factor in ALS progression.
• Senolytic therapies warrant further investigation in ALS preclinical models.
• Careful design is needed to ensure selectivity of senolytic agents for ALS treatment.